Who are Lite Strategy, Inc.'s main suppliers?

Lite Strategy, Inc. (LITS) key suppliers include: GSR-MARKETS-LTD, GSR-STRATEGIES-LLC, ORANY, ORANY. View the full supplier network at chainsifter.com/chain/LITS.

Who are Lite Strategy, Inc.'s major customers?

Lite Strategy, Inc. (LITS) key customers include: KKC-COMMERCIALIZATION-AGREEMENT, CEL-SCI Corporation, CEL-SCI Corporation, UroGen Pharma Ltd., UroGen Pharma Ltd. and 8 more. View the full customer network at chainsifter.com/chain/LITS.

What sector is Lite Strategy, Inc. in?

Lite Strategy, Inc. (LITS) operates in the general sector. ChainSifter tracks its verified supply chain relationships including suppliers, customers, and strategic partners.

Lite Strategy, Inc. Supplier List (LITS): 4 Verified Suppliers

4Suppliers

13Customers

1Debt Items

20Related Chains

Source-Backed Evidence Depth

Lite Strategy, Inc. (LITS) is shown with relationship data already present in ChainSifter's database. Counts below come from stored supply-chain records and filing/source URLs where available; missing source URLs are not filled in or estimated.

19Total relationships

3Distinct source URLs

5High confidence

0.728Average confidence

2026-09-13Latest database update

ChainSifter does not infer unreported suppliers, customers, ownership, acquisitions, debt exposure, revenue dependency, or future supply-chain events on this public page.

Lite Strategy, Inc. Suppliers

Ticker	Name	Confidence	Evidence
GSR-MARKETS-LTD	GSR-MARKETS-LTD	92%	We enter into contracts with GSR Markets Ltd (GSR Markets), an affiliate of GSR Strategies LLC (GSR or Asset Manager), in which we write covered call options on certain of our LTC holdings (Covered C…
GSR-STRATEGIES-LLC	GSR-STRATEGIES-LLC	92%	We enter into contracts with GSR Markets Ltd (GSR Markets), an affiliate of GSR Strategies LLC (GSR or Asset Manager), in which we write covered call options on certain of our LTC holdings (Covered C…
ORANY	ORANY	72%	itionally, post-approval changes in ingredient composition, manufacturing processes or facilities, product labeling, or other areas may require submission of an NDA Supplement to the FDA for review a…
ORANY	ORANY	72%	Reciprocal relationship from ORANY graph: Reciprocal relationship from LITS graph: Reciprocal relationship from ORANY graph: Reciprocal relationship from LITS graph: itionally, post-approval changes …

Lite Strategy, Inc. Customers

Ticker	Name	Confidence	Evidence
KKC-COMMERCIALIZATION-AGREEMENT	KKC-COMMERCIALIZATION-AGREEMENT	92%	We recognized revenue associated with the KKC Commercialization Agreement for the periods presented
CVM	CEL-SCI Corporation	72%	Reciprocal relationship from CVM graph: Reciprocal relationship from LITS graph: compensation decision process, but it does not attempt to set executive compensation to a specific benchmark level, or…
CVM	CEL-SCI Corporation	72%	compensation decision process, but it does not attempt to set executive compensation to a specific benchmark level, or percentile as compared to executive compensation levels at other companies. The …
URGN	UroGen Pharma Ltd.	72%	Reciprocal relationship from URGN graph: Reciprocal relationship from LITS graph: compensation decision process, but it does not attempt to set executive compensation to a specific benchmark level, o…
URGN	UroGen Pharma Ltd.	72%	compensation decision process, but it does not attempt to set executive compensation to a specific benchmark level, or percentile as compared to executive compensation levels at other companies. The …
ANSON-ADVISORS-INC	ANSON-ADVISORS-INC	62%	tion. We continue to evaluate the legal issues that arise concerning transfer of personal data of residents of the European Economic Area (EEA) member states or the U.K. to the U.S. or other jurisdic…
BEIGENE-LTD	BEIGENE-LTD	62%	consideration as the risk of significant revenue reversal will only be resolved depending on future research and development and/or regulatory approval outcomes. We re-evaluate the estimated variable…
BIOATLA-LEAP-THERAPEUTICS-CARDIFF-ONCOLOGY-MOLEC	BIOATLA-LEAP-THERAPEUTICS-CARDIFF-ONCOLOGY-MOLEC	62%	compensation decision process, but it does not attempt to set executive compensation to a specific benchmark level, or percentile as compared to executive compensation levels at other companies. The …
CABLE-CAR-CAPITAL-LLC	CABLE-CAR-CAPITAL-LLC	62%	tion. We continue to evaluate the legal issues that arise concerning transfer of personal data of residents of the European Economic Area (EEA) member states or the U.K. to the U.S. or other jurisdic…
GREEN-DRAGON-INVESTMENT-LLC	GREEN-DRAGON-INVESTMENT-LLC	62%	the Pre-Funded Warrant holders could potentially require “net cash settlement” in a circumstance outside our control. This assessment, which requires the use of professional judgment, is conducted at…
ONCOLOGY-G1-THERAPEUTICS-SYROS-PHARMACEUTICALS-G	ONCOLOGY-G1-THERAPEUTICS-SYROS-PHARMACEUTICALS-G	62%	compensation decision process, but it does not attempt to set executive compensation to a specific benchmark level, or percentile as compared to executive compensation levels at other companies. The …
PRESAGE-BIOSCIENCES-INC	PRESAGE-BIOSCIENCES-INC	62%	consideration as the risk of significant revenue reversal will only be resolved depending on future research and development and/or regulatory approval outcomes. We re-evaluate the estimated variable…
RESTATED-MEI-PHARMA-INC	RESTATED-MEI-PHARMA-INC	62%	compensation decision process, but it does not attempt to set executive compensation to a specific benchmark level, or percentile as compared to executive compensation levels at other companies. The …

Lite Strategy, Inc. Debt Obligations

Instrument	Description	Confidence	Evidence
LITS-DEBT-10723	Warrants outstanding: 6	90%	xbrl warrant detail from xbrl 2023-06-30.

Lite Strategy, Inc. Acquisitions

No acquisitions on recordNo completed or pending acquisitions found in our database for Lite Strategy, Inc..

Lite Strategy, Inc. Ownership

Holder	Name	Confidence	Evidence
LITS-OWNER-VANGUARD-CAPITAL-MANAGEMENT-LLC	VANGUARD CAPITAL MANAGEMENT LLC	90%	13F overlay lists VANGUARD CAPITAL MANAGEMENT LLC as top holder; 37 tracked holders.

Lite Strategy, Inc. Extended Supply Chain Network

Ticker	Name	Chain Index	Hops	Relationship Types
AURA	Aura Biosciences, Inc.	100.00	2
ORANY	ORANGE	100.00	1	['supplier']
AMZE	Amaze Holdings, Inc.	50.00	2
BLTE	Belite Bio, Inc	50.00	2
AYTU	Aytu BioPharma, Inc.	50.00	2
CYCN	Cyclerion Therapeutics, Inc.	50.00	2
DARE	Daré Bioscience, Inc.	50.00	2
DWTX	Dogwood Therapeutics, Inc.	50.00	2
CANF	Can-Fite BioPharma Ltd.	50.00	2
DFTX	Definium Therapeutics, Inc.	50.00	2
CHUC	Charlie's Holdings, Inc.	50.00	2
CLNE	Clean Energy Fuels Corp.	50.00	2
FENC	Fennec Pharmaceuticals Inc.	50.00	2
EQR	Equity Residential	50.00	2
CNOB	ConnectOne Bancorp, Inc.	50.00	2
D	Dominion Energy, Inc.	50.00	2
ESS	Essex Property Trust, Inc.	50.00	2
ED	Consolidated Edison, Inc.	50.00	2
CORT	Corcept Therapeutics Incorporated	50.00	2
CPRX	Catalyst Pharmaceuticals, Inc.	50.00	2

Lite Strategy, Inc. Supply Chain